Arecor Therapeutics announced plans to cease operations within its subsidiary Tetris Pharma during 2025 on Friday, adding ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

(Sharecast News) - Arecor Therapeutics announced plans to cease operations within its subsidiary Tetris Pharma during 2025 on Friday, adding that it had mutually agreed with Xeris BioPharma to ...

CAMBRIDGE, UK - Arecor Therapeutics plc (AIM: LON:AREC), a biopharmaceutical company, today announced the planned orderly cessation of operations at its subsidiary Tetris Pharma during 2025.

CAMBRIDGE, UK - Arecor Therapeutics plc (AIM: LON:AREC), a biopharmaceutical company, today announced the planned orderly cessation of operations at its subsidiary Tetris Pharma during 2025. The move ...

Licensee gains exclusive rights to further develop and commercialise AT351 -AT351 has potential to be the first ...

(Sharecast News) - Arecor Therapeutics announced the signing of an exclusive licensing agreement for AT351, a ready-to-dilute (RTD) liquid formulation of a widely-used critical care therapy ...

Arecor Therapeutics PLC's (AIM:LON:AREC) signing of an exclusive licensing agreement for AT351, a ready-to-dilute formulation of a speciality hospital product, has been welcomed by analysts at Panmure ...

Arecor Therapeutics has entered into an exclusive licensing agreement for AT351, a ready-to-dilute liquid formulation of a critical care therapy, with a major chemicals marketing company’s ...

Shares in Cambridge biopharma company Arecor Therapeutics hit a 52-week low at 54.75p on Friday before recovering to close at ...

Stock markets look set to end the year with a whimper rather than a bang. On London’s last full day of trading of 2024 (the exchange closes at 12.30pm today) the FTSE 100 was down 0.35 per ...